UA78805C2 - Acyloxypyrrolidine derivatives, method for their preparation and therapeutic use - Google Patents

Acyloxypyrrolidine derivatives, method for their preparation and therapeutic use Download PDF

Info

Publication number: UA78805C2
Authority: UA; Ukraine
Prior art keywords: compound; formula; dimethoxyphenyl; sulfonyl; dihydro
Prior art date: 2002-07-19

Application number

UAA200500286A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Sanofi Aventis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-07-19

Filing date

2003-07-17

Publication date

2007-04-25

2003-07-17 Application filed by Sanofi Aventis filed Critical Sanofi Aventis

2007-04-25 Publication of UA78805C2 publication Critical patent/UA78805C2/uk

Links

238000000034 method Methods 0.000 title claims abstract description 16
238000002360 preparation method Methods 0.000 title claims description 7
230000001225 therapeutic effect Effects 0.000 title abstract description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 9
150000001875 compounds Chemical class 0.000 claims description 89
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 21
238000006243 chemical reaction Methods 0.000 claims description 18
150000003839 salts Chemical class 0.000 claims description 18
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 18
229940126062 Compound A Drugs 0.000 claims description 14
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
239000012453 solvate Substances 0.000 claims description 12
239000002253 acid Substances 0.000 claims description 7
206010041067 Small cell lung cancer Diseases 0.000 claims description 6
201000010099 disease Diseases 0.000 claims description 6
150000007529 inorganic bases Chemical class 0.000 claims description 6
150000007530 organic bases Chemical class 0.000 claims description 6
208000000587 small cell lung carcinoma Diseases 0.000 claims description 6
125000000217 alkyl group Chemical group 0.000 claims description 5
208000011580 syndromic disease Diseases 0.000 claims description 5
229910052799 carbon Inorganic materials 0.000 claims description 4
210000003734 kidney Anatomy 0.000 claims description 4
229940127554 medical product Drugs 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 4
AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 claims description 4
210000002784 stomach Anatomy 0.000 claims description 4
208000019901 Anxiety disease Diseases 0.000 claims description 3
YUDRVAHLXDBKSR-UHFFFAOYSA-N [CH]1CCCCC1 Chemical compound [CH]1CCCCC1 YUDRVAHLXDBKSR-UHFFFAOYSA-N 0.000 claims description 3
230000036506 anxiety Effects 0.000 claims description 3
125000000753 cycloalkyl group Chemical group 0.000 claims description 3
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 3
239000000945 filler Substances 0.000 claims description 3
201000001320 Atherosclerosis Diseases 0.000 claims description 2
HNUALPPJLMYHDK-UHFFFAOYSA-N C[CH]C Chemical compound C[CH]C HNUALPPJLMYHDK-UHFFFAOYSA-N 0.000 claims description 2
208000005171 Dysmenorrhea Diseases 0.000 claims description 2
206010013935 Dysmenorrhoea Diseases 0.000 claims description 2
206010022489 Insulin Resistance Diseases 0.000 claims description 2
208000008589 Obesity Diseases 0.000 claims description 2
208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 2
206010033664 Panic attack Diseases 0.000 claims description 2
206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
125000003277 amino group Chemical group 0.000 claims description 2
210000000748 cardiovascular system Anatomy 0.000 claims description 2
QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 claims description 2
208000006575 hypertriglyceridemia Diseases 0.000 claims description 2
WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 claims description 2
235000020824 obesity Nutrition 0.000 claims description 2
208000019906 panic disease Diseases 0.000 claims description 2
208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
208000005107 Premature Birth Diseases 0.000 claims 1
206010036590 Premature baby Diseases 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
102000005962 receptors Human genes 0.000 description 32
108020003175 receptors Proteins 0.000 description 32
239000000203 mixture Substances 0.000 description 26
239000002904 solvent Substances 0.000 description 23
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 18
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 18
-1 for example Chemical class 0.000 description 18
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
239000002585 base Substances 0.000 description 14
239000000047 product Substances 0.000 description 12
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 11
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 9
238000003756 stirring Methods 0.000 description 9
241000282414 Homo sapiens Species 0.000 description 8
239000000243 solution Substances 0.000 description 8
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 7
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 7
208000035475 disorder Diseases 0.000 description 7
239000012074 organic phase Substances 0.000 description 7
239000011541 reaction mixture Substances 0.000 description 7
WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 7
102400000059 Arg-vasopressin Human genes 0.000 description 6
101800001144 Arg-vasopressin Proteins 0.000 description 6
206010028980 Neoplasm Diseases 0.000 description 6
241000700159 Rattus Species 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
125000004432 carbon atom Chemical group C* 0.000 description 6
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 6
238000010992 reflux Methods 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
102000004136 Vasopressin Receptors Human genes 0.000 description 5
108090000643 Vasopressin Receptors Proteins 0.000 description 5
210000004100 adrenal gland Anatomy 0.000 description 5
235000019439 ethyl acetate Nutrition 0.000 description 5
BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 5
210000004185 liver Anatomy 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
230000002265 prevention Effects 0.000 description 5
101800000414 Corticotropin Proteins 0.000 description 4
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 4
229960000258 corticotropin Drugs 0.000 description 4
210000000496 pancreas Anatomy 0.000 description 4
230000001575 pathological effect Effects 0.000 description 4
239000000741 silica gel Substances 0.000 description 4
229910002027 silica gel Inorganic materials 0.000 description 4
230000035882 stress Effects 0.000 description 4
239000000126 substance Substances 0.000 description 4
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 3
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 3
PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 3
102100027708 Astrotactin-1 Human genes 0.000 description 3
239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 3
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical class CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
241000282412 Homo Species 0.000 description 3
101000936741 Homo sapiens Astrotactin-1 Proteins 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
229960002478 aldosterone Drugs 0.000 description 3
150000001408 amides Chemical class 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
210000003169 central nervous system Anatomy 0.000 description 3
239000013078 crystal Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
150000004677 hydrates Chemical class 0.000 description 3
229960000890 hydrocortisone Drugs 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
239000012429 reaction media Substances 0.000 description 3
239000012047 saturated solution Substances 0.000 description 3
239000007787 solid Substances 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
210000004291 uterus Anatomy 0.000 description 3
FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 2
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
SFWWGMKXCYLZEG-UHFFFAOYSA-N 3-methylmorpholine Chemical compound CC1COCCN1 SFWWGMKXCYLZEG-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
239000000275 Adrenocorticotropic Hormone Substances 0.000 description 2
102000017924 CHRM4 Human genes 0.000 description 2
102400000739 Corticotropin Human genes 0.000 description 2
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
206010028813 Nausea Diseases 0.000 description 2
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
206010047163 Vasospasm Diseases 0.000 description 2
101100107916 Xenopus laevis chrm4 gene Proteins 0.000 description 2
230000009471 action Effects 0.000 description 2
229910052784 alkaline earth metal Inorganic materials 0.000 description 2
150000008064 anhydrides Chemical class 0.000 description 2
230000002686 anti-diuretic effect Effects 0.000 description 2
239000003849 aromatic solvent Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000001772 blood platelet Anatomy 0.000 description 2
ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
150000003943 catecholamines Chemical class 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
238000001816 cooling Methods 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
235000019253 formic acid Nutrition 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
210000003016 hypothalamus Anatomy 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
230000008693 nausea Effects 0.000 description 2
150000002825 nitriles Chemical class 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
238000003752 polymerase chain reaction Methods 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
230000028327 secretion Effects 0.000 description 2
238000007711 solidification Methods 0.000 description 2
230000008023 solidification Effects 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
229940014800 succinic anhydride Drugs 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
239000003826 tablet Substances 0.000 description 2
238000004448 titration Methods 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
ONRNRVLJHFFBJG-UHFFFAOYSA-N 1,2-di(imidazol-1-yl)ethane-1,2-dione Chemical compound C1=CN=CN1C(=O)C(=O)N1C=CN=C1 ONRNRVLJHFFBJG-UHFFFAOYSA-N 0.000 description 1
DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
UIHCLUNTQKBZGK-UHFFFAOYSA-N 3-methyl-2-pentanone Chemical compound CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
KDKUVYLMPJIGKA-UHFFFAOYSA-N 4-[[5-amino-1-[(2,6-difluorophenyl)-oxomethyl]-1,2,4-triazol-3-yl]amino]benzenesulfonamide Chemical compound N=1N(C(=O)C=2C(=CC=CC=2F)F)C(N)=NC=1NC1=CC=C(S(N)(=O)=O)C=C1 KDKUVYLMPJIGKA-UHFFFAOYSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
239000004382 Amylase Substances 0.000 description 1
102400000344 Angiotensin-1 Human genes 0.000 description 1
101800000734 Angiotensin-1 Proteins 0.000 description 1
108010064733 Angiotensins Proteins 0.000 description 1
102000015427 Angiotensins Human genes 0.000 description 1
208000000103 Anorexia Nervosa Diseases 0.000 description 1
206010003225 Arteriospasm coronary Diseases 0.000 description 1
229910015900 BF3 Inorganic materials 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
206010048962 Brain oedema Diseases 0.000 description 1
208000032841 Bulimia Diseases 0.000 description 1
206010006550 Bulimia nervosa Diseases 0.000 description 1
102000017925 CHRM3 Human genes 0.000 description 1
101150060249 CHRM3 gene Proteins 0.000 description 1
208000020446 Cardiac disease Diseases 0.000 description 1
208000002177 Cataract Diseases 0.000 description 1
206010008111 Cerebral haemorrhage Diseases 0.000 description 1
206010059109 Cerebral vasoconstriction Diseases 0.000 description 1
101800001982 Cholecystokinin Proteins 0.000 description 1
102100025841 Cholecystokinin Human genes 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 1
108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
208000027534 Emotional disease Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
208000001640 Fibromyalgia Diseases 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
102400000921 Gastrin Human genes 0.000 description 1
108010052343 Gastrins Proteins 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
102400000321 Glucagon Human genes 0.000 description 1
108060003199 Glucagon Proteins 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
208000013016 Hypoglycemia Diseases 0.000 description 1
206010066151 Hyponatraemic encephalopathy Diseases 0.000 description 1
206010062767 Hypophysitis Diseases 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
239000002841 Lewis acid Substances 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
208000026139 Memory disease Diseases 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
208000019022 Mood disease Diseases 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
206010062575 Muscle contracture Diseases 0.000 description 1
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
241001274216 Naso Species 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
201000005118 Nephrogenic diabetes insipidus Diseases 0.000 description 1
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
206010029897 Obsessive thoughts Diseases 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
208000006399 Premature Obstetric Labor Diseases 0.000 description 1
206010036600 Premature labour Diseases 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
208000003782 Raynaud disease Diseases 0.000 description 1
208000012322 Raynaud phenomenon Diseases 0.000 description 1
108010086019 Secretin Proteins 0.000 description 1
102100037505 Secretin Human genes 0.000 description 1
208000005392 Spasm Diseases 0.000 description 1
241000282887 Suidae Species 0.000 description 1
208000033781 Thyroid carcinoma Diseases 0.000 description 1
208000024770 Thyroid neoplasm Diseases 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
208000007814 Unstable Angina Diseases 0.000 description 1
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
108010004977 Vasopressins Proteins 0.000 description 1
102000002852 Vasopressins Human genes 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
238000012084 abdominal surgery Methods 0.000 description 1
239000003377 acid catalyst Substances 0.000 description 1
230000009858 acid secretion Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
201000005179 adrenal carcinoma Diseases 0.000 description 1
201000005188 adrenal gland cancer Diseases 0.000 description 1
201000003352 adrenal gland pheochromocytoma Diseases 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
230000036626 alertness Effects 0.000 description 1
239000003513 alkali Substances 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
230000007815 allergy Effects 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
238000002399 angioplasty Methods 0.000 description 1
ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
238000009835 boiling Methods 0.000 description 1
208000006752 brain edema Diseases 0.000 description 1
208000003362 bronchogenic carcinoma Diseases 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
229940107137 cholecystokinin Drugs 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000037326 chronic stress Effects 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
206010009887 colitis Diseases 0.000 description 1
238000002591 computed tomography Methods 0.000 description 1
208000006111 contracture Diseases 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
RVOJTCZRIKWHDX-UHFFFAOYSA-N cyclohexanecarbonyl chloride Chemical compound ClC(=O)C1CCCCC1 RVOJTCZRIKWHDX-UHFFFAOYSA-N 0.000 description 1
NZNMSOFKMUBTKW-UHFFFAOYSA-M cyclohexanecarboxylate Chemical compound [O-]C(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-M 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
206010013663 drug dependence Diseases 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000006397 emotional response Effects 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000002550 fecal effect Effects 0.000 description 1
230000035558 fertility Effects 0.000 description 1
239000007789 gas Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
230000030136 gastric emptying Effects 0.000 description 1
239000003629 gastrointestinal hormone Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
229960004666 glucagon Drugs 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
230000004116 glycogenolysis Effects 0.000 description 1
239000008187 granular material Substances 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
230000002008 hemorrhagic effect Effects 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
230000002631 hypothermal effect Effects 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
QNLOWBMKUIXCOW-UHFFFAOYSA-N indol-2-one Chemical compound C1=CC=CC2=NC(=O)C=C21 QNLOWBMKUIXCOW-UHFFFAOYSA-N 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
208000001286 intracranial vasospasm Diseases 0.000 description 1
208000002551 irritable bowel syndrome Diseases 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
238000002955 isolation Methods 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
235000015110 jellies Nutrition 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
150000007517 lewis acids Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000004807 localization Effects 0.000 description 1
239000006210 lotion Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
210000000713 mesentery Anatomy 0.000 description 1
229940043265 methyl isobutyl ketone Drugs 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
239000002395 mineralocorticoid Substances 0.000 description 1
201000003152 motion sickness Diseases 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
239000002674 ointment Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
230000036407 pain Effects 0.000 description 1
230000037324 pain perception Effects 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
208000019899 phobic disease Diseases 0.000 description 1
210000003635 pituitary gland Anatomy 0.000 description 1
229940037129 plain mineralocorticoids for systemic use Drugs 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
208000026440 premature labor Diseases 0.000 description 1
230000008569 process Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
239000003368 psychostimulant agent Substances 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
208000002815 pulmonary hypertension Diseases 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
230000029865 regulation of blood pressure Effects 0.000 description 1
210000005227 renal system Anatomy 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
229960002101 secretin Drugs 0.000 description 1
OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
230000009329 sexual behaviour Effects 0.000 description 1
IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
241000894007 species Species 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
238000005507 spraying Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000002438 stress hormone Substances 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
239000000725 suspension Substances 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
201000002510 thyroid cancer Diseases 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
208000013077 thyroid gland carcinoma Diseases 0.000 description 1
FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
230000025033 vasoconstriction Effects 0.000 description 1
229960003726 vasopressin Drugs 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
239000008096 xylene Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Anesthesiology (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Psychiatry (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Pyrrole Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

UAA200500286A 2002-07-19 2003-07-17 Acyloxypyrrolidine derivatives, method for their preparation and therapeutic use UA78805C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0209242A FR2842527B1 (fr)	2002-07-19	2002-07-19	Derives d'acyloxypyrolidine, leur preparation et leur application en therapeutique
PCT/FR2003/002262 WO2004009585A2 (fr)	2002-07-19	2003-07-17	Derives d'acyloxypyrrolidine et leur utilisation en tant que ligands des recepteurs v1b et v1a de avp

Publications (1)

Publication Number	Publication Date
UA78805C2 true UA78805C2 (en)	2007-04-25

Family

ID=29797610

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA200500286A UA78805C2 (en)	2002-07-19	2003-07-17	Acyloxypyrrolidine derivatives, method for their preparation and therapeutic use

Country Status (27)

Country	Link
US (1)	US7202267B2 (pl)
EP (1)	EP1525198B1 (pl)
JP (1)	JP4264414B2 (pl)
CN (1)	CN100425608C (pl)
AR (1)	AR040571A1 (pl)
AT (1)	ATE312092T1 (pl)
AU (1)	AU2003271815B8 (pl)
BR (1)	BR0312800A (pl)
CA (1)	CA2492224A1 (pl)
DE (1)	DE60302670T2 (pl)
DK (1)	DK1525198T3 (pl)
EA (1)	EA008444B1 (pl)
ES (1)	ES2254962T3 (pl)
FR (1)	FR2842527B1 (pl)
HR (1)	HRP20041231A2 (pl)
IL (1)	IL165942A (pl)
IS (1)	IS2487B (pl)
ME (1)	MEP12408A (pl)
MX (1)	MXPA05000822A (pl)
NO (1)	NO20050292L (pl)
NZ (1)	NZ537615A (pl)
PL (1)	PL375309A1 (pl)
RS (1)	RS20050018A (pl)
TW (1)	TWI274751B (pl)
UA (1)	UA78805C2 (pl)
WO (1)	WO2004009585A2 (pl)
ZA (1)	ZA200500478B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1659121A4 (en)	2003-08-28	2008-11-26	Taisho Pharmaceutical Co Ltd	1,3-dihydro-2H-indol-2-one derivative
TW200643015A (en)	2005-03-11	2006-12-16	Akzo Nobel Nv	2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives
DE102005015957A1 (de) *	2005-03-31	2006-10-05	Abbott Gmbh & Co. Kg	Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
CA2610400A1 (en)	2005-06-07	2006-12-14	Pharmacopeia, Inc.	Azinone and diazinone v3 inhibitors for depression and stress disorders
NZ575426A (en)	2006-09-11	2010-09-30	Organon Nv	Quinazolinone and isoquinolinone acetamide derivatives useful for the treatment of disorders which are influenced by modulation of the activity of the hpa axis
CN103864658B (zh) *	2014-03-06	2016-06-15	南京工业大学	氮杂环丁酮衍生物及其制备方法与应用
CN104447489B (zh) *	2014-12-29	2017-01-11	南京工业大学	3,4-二芳基马来酰亚胺衍生物及其制备方法与应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2804114B1 (fr) *	2000-01-25	2002-03-08	Sanofi Synthelabo	Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant

2002
- 2002-07-19 FR FR0209242A patent/FR2842527B1/fr not_active Expired - Fee Related
2003
- 2003-07-15 AR AR20030102539A patent/AR040571A1/es unknown
- 2003-07-17 WO PCT/FR2003/002262 patent/WO2004009585A2/fr not_active Ceased
- 2003-07-17 CA CA002492224A patent/CA2492224A1/en not_active Abandoned
- 2003-07-17 MX MXPA05000822A patent/MXPA05000822A/es active IP Right Grant
- 2003-07-17 CN CNB038218178A patent/CN100425608C/zh not_active Expired - Fee Related
- 2003-07-17 HR HR20041231A patent/HRP20041231A2/hr not_active Application Discontinuation
- 2003-07-17 EA EA200500032A patent/EA008444B1/ru not_active IP Right Cessation
- 2003-07-17 EP EP03753652A patent/EP1525198B1/fr not_active Expired - Lifetime
- 2003-07-17 RS YUP-2005/0018A patent/RS20050018A/sr unknown
- 2003-07-17 ES ES03753652T patent/ES2254962T3/es not_active Expired - Lifetime
- 2003-07-17 JP JP2004522252A patent/JP4264414B2/ja not_active Expired - Fee Related
- 2003-07-17 AU AU2003271815A patent/AU2003271815B8/en not_active Ceased
- 2003-07-17 PL PL03375309A patent/PL375309A1/pl not_active IP Right Cessation
- 2003-07-17 DK DK03753652T patent/DK1525198T3/da active
- 2003-07-17 BR BR0312800-8A patent/BR0312800A/pt not_active IP Right Cessation
- 2003-07-17 DE DE60302670T patent/DE60302670T2/de not_active Expired - Lifetime
- 2003-07-17 ME MEP-124/08A patent/MEP12408A/xx unknown
- 2003-07-17 UA UAA200500286A patent/UA78805C2/uk unknown
- 2003-07-17 AT AT03753652T patent/ATE312092T1/de active
- 2003-07-17 NZ NZ537615A patent/NZ537615A/en not_active IP Right Cessation
- 2003-07-18 TW TW092119736A patent/TWI274751B/zh not_active IP Right Cessation
2004
- 2004-12-22 IL IL165942A patent/IL165942A/en not_active IP Right Cessation
2005
- 2005-01-12 IS IS7641A patent/IS2487B/is unknown
- 2005-01-18 ZA ZA200500478A patent/ZA200500478B/xx unknown
- 2005-01-19 NO NO20050292A patent/NO20050292L/no not_active Application Discontinuation
- 2005-01-19 US US11/038,384 patent/US7202267B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
IS7641A (is)	2005-01-12
AU2003271815A1 (en)	2004-02-09
IS2487B (is)	2008-12-15
RS20050018A (sr)	2007-06-04
NZ537615A (en)	2006-11-30
ES2254962T3 (es)	2006-06-16
ZA200500478B (en)	2006-07-26
CN100425608C (zh)	2008-10-15
IL165942A (en)	2010-04-15
AR040571A1 (es)	2005-04-13
EA008444B1 (ru)	2007-06-29
IL165942A0 (en)	2006-01-15
ATE312092T1 (de)	2005-12-15
FR2842527B1 (fr)	2005-01-28
MEP12408A (en)	2010-06-10
NO20050292L (no)	2005-04-19
EP1525198B1 (fr)	2005-12-07
DE60302670D1 (de)	2006-01-12
AU2003271815B8 (en)	2009-04-30
HK1074444A1 (en)	2005-11-11
MXPA05000822A (es)	2005-08-29
US20050192335A1 (en)	2005-09-01
BR0312800A (pt)	2005-04-19
US7202267B2 (en)	2007-04-10
EA200500032A1 (ru)	2005-08-25
TWI274751B (en)	2007-03-01
TW200410957A (en)	2004-07-01
FR2842527A1 (fr)	2004-01-23
PL375309A1 (pl)	2005-11-28
CN1681806A (zh)	2005-10-12
DE60302670T2 (de)	2006-09-07
JP4264414B2 (ja)	2009-05-20
CA2492224A1 (en)	2004-01-29
WO2004009585A3 (fr)	2004-05-06
WO2004009585A2 (fr)	2004-01-29
AU2003271815B2 (en)	2009-03-12
EP1525198A2 (fr)	2005-04-27
JP2005537271A (ja)	2005-12-08
HRP20041231A2 (en)	2005-02-28
DK1525198T3 (da)	2006-04-18

Publication	Publication Date	Title
JP3992498B2 (ja)	2007-10-17	新規１，３−ジヒドロ−２ｈ−インドール−２−オン誘導体、それらの製造法およびそれらを含む医薬組成物
JP4861591B2 (ja)	2012-01-25	新規な１，３−ジヒドロ−２ｈ−インドール−２−オン誘導体、それらの製法およびそれらを含有する医薬組成物
US6596732B2 (en)	2003-07-22	1,3-dihydro-2h-indol-2-one, preparation method and pharmaceutical compositions containing same
CN101184395A (zh)	2008-05-21	包含二芳基胺的化合物和组合物及其作为类固醇激素核受体调节剂的用途
JP2016519674A (ja)	2016-07-07	過剰増殖障害を治療または予防するための３−アセチルアミノ−１−（フェニル−ヘテロアリール−アミノカルボニルまたはフェニル−ヘテロアリール−カルボニルアミノ）ベンゼン誘導体
CN1964944A (zh)	2007-05-16	作为抗病毒药的吲哚衍生物
JPH09509169A (ja)	1997-09-16	エストロゲンに関連する新生物及び病気の処置に有用な新規なインドール誘導体類
CN102666526A (zh)	2012-09-12	作为ccr1受体拮抗剂的吲唑和吡唑并吡啶化合物
JPH0578350A (ja)	1993-03-30	ヒドラゾン誘導体、その製造方法及びその使用方法
KR20100126401A (ko)	2010-12-01	신규한 ３-아미노알킬-１,３-디히드로-２ｈ-인돌-２-온 유도체, 그의 제법 및 그의 치료학적 용도
KR20100051812A (ko)	2010-05-18	3-위치에서 이치환된 인돌-2-온 유도체, 그의 제조 및 그의 치료적 용도
JP2011518213A (ja)	2011-06-23	１，３−ジヒドロ−２Ｈ−ピロロ［３，２−ｂ］ピリジン−２−オン誘導体、この調製、およびこの治療用途
JP4264414B2 (ja)	2009-05-20	アシルオキシピロリジン、その製造法および治療における適用
WO2021129629A1 (zh)	2021-07-01	Zeste增强子同源物2抑制剂及其用途
MX2011008546A (es)	2011-11-18	Derivados de 3-benzofuranil-indol-2-ona-3-acetamidopiperazinas sustituidos, su preparacion y su uso en terapeutica.
KR20050019896A (ko)	2005-03-03	아실옥시피롤리딘 유도체, 및 ｖ1ｂ 수용체 또는 ｖ1ｂ 및ｖ1ａ 수용체 모두의 리간드로서의 그의 용도
JP2024525791A (ja)	2024-07-12	治療に使用するためのイミダゾ［１，２－ｂ］［１，２，４］トリアゾール誘導体
HK1074444B (en)	2006-07-14	Acyloxypyrrolidine derivatives, preparation and therapeutic use thereof
TW201221127A (en)	2012-06-01	Sulfamide derivatives having NPY Y5 receptor antagonistic activity
HK1173729A (en)	2013-05-24	Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists